Uncharted waters: Navigating requests for experimental medicines
In May 2018, the federal Right-to-Try Act was signed into law, claiming a new and improved option for patients with no therapeutic options to obtain
Read More
The perils of partnering for profit
Editor’s note: The opinions expressed in the following blog post are the author’s own and do not reflect the views of Baylor College of Medicine.
Read More
The gene therapy watchers: Can an NIH advisory committee reinvent itself?
Francis Collins, NIH Director, and Scott Gottlieb, FDA Commissioner, recently announced plans to eliminate oversight of new gene therapy experiments by the NIH’s Recombinant DNA
Read More
CRISPR: A democratizing technology calls for democratic dialogue
By now, you may have read stories about a gene editing technique called CRISPR/Cas9. CRISPR is poised to revolutionize the biological sciences because it’s the
Read More
A ‘right to try,’ but at what cost?
A few weeks ago, my colleague Stephanie Morain wrote a PolicyWise post on attempts to pass so-called “right-to-try” legislation in the U.S. House of Representatives.
Read More
Life played richly: Learn to live a life of fulfillment
In her critically acclaimed one-person show, Let Me Down Easy, Anna Deavere Smith re-enacts interviews with people observing the rich identity of the human body,
Read More
Gene therapy: An out-of-body experience
On April 1, 2016, the European Medicines Agency (EMA) approved the first ex-vivo (outside the body) gene therapy in the Western Hemisphere. Diseased stem cells
Read More